- Conditions
- Stage III Uterine Corpus Leiomyosarcoma AJCC v8, Stage IV Uterine Corpus Leiomyosarcoma AJCC v8, Uterine Corpus Leiomyosarcoma
- Interventions
- Computed Tomography, Core Biopsy, Magnetic Resonance Imaging, Olaparib, Temozolomide
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 15
- States / cities
- Phoenix, Arizona • Palo Alto, California • Aurora, Colorado + 11 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1153–1176
of 3,890
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Prostatic Neoplasm
- Interventions
- radioimmuniguided intenstiy modulated radiotherapy
- Radiation
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Prostate Cancer
- Interventions
- 99mTc-MIP-1404 Injection, Whole-Body Planar and pelvic SPECT/CT scan
- Drug · Diagnostic Test
- Lead sponsor
- Molecular Insight Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 531 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 33
- States / cities
- Duarte, California • Los Angeles, California • San Francisco, California + 26 more
- Conditions
- Head and Neck Cancer
- Interventions
- 99mTc-EC-DG
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Liver Fibrosis, Pulmonary Fibrosis, Myocardial Fibrosis
- Interventions
- 68Ga-FAP-2286, Positron Emission Tomography (PET)
- Drug · Procedure
- Lead sponsor
- Thomas Hope
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Locally Advanced Cholangiocarcinoma, Metastatic Cholangiocarcinoma, Recurrent Cholangiocarcinoma, Stage III Hilar Cholangiocarcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Hilar Cholangiocarcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8
- Interventions
- Biopsy, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Sacituzumab Govitecan
- Procedure · Biological
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Urgency Urinary Incontinence
- Interventions
- Brain functional MRI with simplified urodynamics
- Other
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 217 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Lung Carcinoma Metastatic in the Brain, Stage IV Lung Non-Small Cell Cancer AJCC v7
- Interventions
- Ferumoxytol, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Pembrolizumab
- Drug · Other · Procedure + 1 more
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Clear Cell Renal Cell Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lymph Nodes, Metastatic Malignant Neoplasm in the Soft Tissue, Metastatic Malignant Neoplasm in the Viscera, Rhabdoid Tumor of the Kidney, Sarcomatoid Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
- Interventions
- Biospecimen Collection, Bone Scan, Cabozantinib, Computed Tomography, Ipilimumab, Magnetic Resonance Imaging, Nivolumab, Quality-of-Life Assessment, Questionnaire Administration
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 1,175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 858
- States / cities
- Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 554 more
- Conditions
- Liver Cancer, Adult
- Interventions
- 3D-MPUS
- Diagnostic Test
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 3
- States / cities
- Palo Alto, California • San Diego, California • Philadelphia, Pennsylvania
- Conditions
- Myelodysplastic Syndrome With Excess Blasts, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome/Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Syndrome, Refractory Myelodysplastic Syndrome/Acute Myeloid Leukemia
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Echocardiography Test, Multigated Acquisition Scan, UAE Inhibitor TAK-243
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 4
- States / cities
- Tampa, Florida • Chicago, Illinois • Columbus, Ohio + 1 more
- Conditions
- Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- vismodegib, sirolimus, positron emission tomography, computed tomography, pharmacological study, laboratory biomarker analysis, fludeoxyglucose F 18
- Drug · Procedure · Other + 1 more
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
- Conditions
- Adolescent Idiopathic Scoliosis
- Interventions
- Momentum Application
- Device
- Lead sponsor
- Children's Hospital Los Angeles
- Other
- Eligibility
- 8 Years to 18 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Brain Metastases, Brain Metastases, Adult, Brain Cancer
- Interventions
- 18F fluciclovine
- Drug
- Lead sponsor
- Baptist Health South Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2033
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Resectable Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Ductal Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma
- Interventions
- Samuraciclib, Computed Tomography, Endoscopic Ultrasound Biopsy, Biospecimen Collection
- Drug · Procedure
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
- Interventions
- Biospecimen Collection, Computed Tomography, Cyclophosphamide, Fludarabine, Leukapheresis, Positron Emission Tomography, Tisagenlecleucel, Total-Body Irradiation
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- Nathan Denlinger
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Breast Cancer
- Interventions
- CBCT Scan, OBI KV Imaging
- Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Childhood Brain Tumor
- Interventions
- Neurocognitive testing, rsfcMRI
- Other · Device
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 4 Years to 18 Years
- Enrollment
- 154 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2027
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Pregnancy Related
- Interventions
- Pulsenmore ES home ultrasound
- Device
- Lead sponsor
- PulseNmore
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Boston, Massachusetts
- Conditions
- Lung Cancer
- Interventions
- Sputum sample, Pulmonary function tests, Computerized tomography (CT) scan of the chest, Buccal epithelium collection, Nasal brushings, Bronchoscopy, Bronchoalveolar lavage, Blood sample collection, Urine sample, Questionnaire-data collection
- Procedure · Radiation · Other
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 55 Years to 80 Years
- Enrollment
- 480 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2026
- U.S. locations
- 2
- States / cities
- Nashville, Tennessee
- Conditions
- Prostate Carcinoma
- Interventions
- Biopsy of Prostate, Biospecimen Collection, Computed Tomography, Flotufolastat F-18 Gallium, Positron Emission Tomography
- Procedure · Radiation
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 90 Years · Male only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2037
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Coronary Artery Calcification
- Interventions
- Notification
- Other
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 84 Years
- Enrollment
- 202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Staphylococcus Aureus Bacteremia
- Interventions
- Cefazolin, Penicillin, Clindamycin, Vancomycin, Effectiveness of early switch to oral antibiotics, Whole body FDG PET/CT Imaging
- Drug · Other · Radiation
- Lead sponsor
- University of Melbourne
- Other
- Eligibility
- Not listed
- Enrollment
- 8,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Advanced Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Unresectable Acral Lentiginous Melanoma, Unresectable Melanoma, Unresectable Mucosal Melanoma
- Interventions
- Ipilimumab, Nivolumab, Patient Observation, Pembrolizumab
- Biological · Other
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 482
- States / cities
- Fairhope, Alabama • Mobile, Alabama • Fairbanks, Alaska + 330 more